Table 1.
Patient, tumor and treatment characteristics.
| All Patients (n=136) | Grade 0-1 RP (n=96) | ≥Grade 2 RP (n=40) | ≥Grade 3 RP (n=19) | |
|---|---|---|---|---|
|
| ||||
| Patient Characteristics | ||||
|
| ||||
| Median Age (range) | 66.7 (37.2-85.2) | 66.8 (37.2-85.3) | 61.4 (48.0-83.7) | 63.9 (51.2-83.4) |
|
| ||||
| Male | 67 (49.3%) | 41 (42.7%) | 26 (65.0%) | 15 (79.0%) |
| Female | 69 (50.7%) | 55 (57.3%) | 14 (35.0%) | 4 (21.0%) |
|
| ||||
| ECOG PS | ||||
| 0 | 62 (45.6%) | 45 (46.9%) | 17 (42.5%) | 7 (36.8%) |
| 1 | 67 (49.3%) | 49 (51.0%) | 18 (45.0%) | 9 (47.4%) |
| 2 | 7 (5.1%) | 2 (2.1%) | 5 (12.5%) | 3 (15.8%) |
|
| ||||
| Smoking Status | ||||
| Current | 48 (35.3%) | 37 (38.5%) | 11 (27.5%) | 6 (31.6%) |
| Former | 74 (54.4%) | 48 (50.0%) | 26 (65.0%) | 12 (63.2%) |
| Never | 14 (10.3%) | 11 (11.5%) | 3 (7.5%) | 1 (5.3%) |
|
| ||||
| Median Pack-years (range) | 49 (0-200) | 49 (0-200) | 40 (0-150) | 55 (0-120) |
|
| ||||
| Median FEV1 in Liters (range) | 1.98 (0.66-4.31; n=115) |
1.99 (0.74-4.31; n=81) | .98 (0.66-3.44; n=34) | .98 (0.92-3.44; n=18) |
|
| ||||
| Tumor Characteristics | ||||
|
| ||||
| Histology: | ||||
| Squamous cell carcinoma | 29 (21.3%) | 19 (19.8%) | 10 (25.0%) | 5 (26.3%) |
| Adenocarcinoma | 64 (47.1%) | 49 (51.0%) | 15 (37.5%) | 5 (26.3%) |
| Poor differentiated carcinoma† | 28 (20.6%) | 17 (17.7%) | 11 (27.5%) | 7 (36.8%) |
| Small cell lung cancer | 15 (11.0%) | 11 (11.5%) | 4 (10.0%) | 2 (10.5%) |
|
| ||||
| T-stage | ||||
| 0 | 6 (4.4%) | 4 (4.2%) | 2 (5.0%) | 2 (10.5%) |
| 1 | 31 (22.8%) | 26 (27.1%) | 5 (12.5%) | 1 (5.3%) |
| 2 | 47 (34.6%) | 30 (31.2%) | 17 (42.5%) | 8 (42.1%) |
| 3 | 24 (17.6%) | 15 (15.6%) | 9 (22.5%) | 4 (21.0%) |
| 4 | 28 (20.6%) | 21 (21.9%) | 7 (17.5%) | 4 (21.0%) |
|
| ||||
| N-stage | ||||
| 0 | 10 (7.4%) | 10 (10.4%) | 0 (0.0%) | 0 (0.0%) |
| 1 | 11 (8.1%) | 10 (10.4%) | 1 (2.5%) | 0 (0.0%) |
| 2 | 80 (58.8%) | 53 (55.2%) | 27 (67.5%) | 14 (73.7%) |
| 3 | 35 (25.7%) | 23 (24.0%) | 12 (30.0%) | 5 (26.3%) |
|
| ||||
| Stage | ||||
| IIB | 9 (6.6%) | 9 (9.4%) | 0 (0.0%) | 0 (0.0%) |
| IIIA | 63 (46.3%) | 40 (41.7%) | 23 (57.5%) | 11 (57.9%) |
| IIIB | 52 (38.2%) | 38 (39.6%) | 14 (35.0%) | 7 (36.8%) |
| IV | 12 (8.8%) | 9 (9.4%) | 3 (7.5%) | 1 (5.3%) |
|
| ||||
| Treatment Characteristics | ||||
|
| ||||
| Median Radiation Dose (range) | 63 Gy (41.4-72.7) | 63 Gy (45-72) | 66.6 Gy (41.4-72.7) | 66.6 Gy (41.4-72.7) |
|
| ||||
| Radiation Technique: | ||||
| 3D Conformal | 34 (25%) | 26 (27.1%) | 8 (20.0%) | 2 (10.5%) |
| IMRT | 102 (75%) | 70 (72.9%) | 32 (80.0%) | 17 ( 89.5%) |
|
| ||||
| Simulation Technique: | ||||
| 3D-CT | 72 (52.9%) | 53 (55.2%) | 19 (47.5%) | 8 (42.1%) |
| 4D CT | 64 (47.1%) | 43 (44.8%) | 21 (52.5%) | 11 (57.9%) |
|
| ||||
| Radiation Sequencing: | ||||
| Pre-operative | 15 (11.0%) | 13 (13.5%) | 2 (5.0%) | 0 (0.0%) |
| Radiation alone | 106 (78.0%) | 69 (71.9%) | 37 (92.5%) | 19 (100%) |
| Post-operative | 15 (11.0%) | 14 (14.6%) | 1 (2.5%) | 0 (0.0%) |
|
| ||||
| Surgery | 30 (22.8%) | 27 (28.1%) | 3 (7.5%) | 0 (0.0%) |
|
| ||||
| Surgery Type | ||||
| Wedge | 4 (13.3%) | 4 (14.8%) | 0 | - |
| Lobectomy | 25 (83.3%) | 22 (81.5%) | 3 (100%) | - |
| Pneumonectomy | 1 (3.3%) | 1 (3.7%) | 0 | - |
|
| ||||
| Any Chemotherapy | 130 (95.6%) | 91 (94.8%) | 39 (97.5%) | 18 (94.7%) |
|
| ||||
| Induction Chemotherapy | 11 (8.1%) | 10 (10.4%) | 1 (2.5%) | 1 (5.3%) |
|
| ||||
| Concurrent Chemotherapy | 121 (89.0%) | 82 (85.4%) | 39 (97.5%) | 18 (94.7%) |
|
| ||||
| Consolidation Chemotherapy | 78 (57.4%) | 54 (56.3%) | 24 (60.0%) | 5 (26.3%) |
|
| ||||
| Consolidation Docetaxel | 16 (11.8%) | 9 (8.3%) | 8 (20.0%) | 3 (15.8%) |
|
| ||||
| Bilateral Lung Dose-Volume Histogram | ||||
|
| ||||
| Median V5 (range) | 61.7% (21.7-97.2%) | 59.4% (21.7-95.0%) | 65.3% (38.0 - 97.2%) | 63.8% (42.0-97.2%) |
|
| ||||
| Median V20 (range) | 34.0% (9.4-70.0%) | 32.4% (9.6-68.7%) | 36.3% (21.9-70.0%) | 36.4% (22.0-68.0%) |
|
| ||||
| Median MLD (range) | 18.1 Gy (6.1-32.4 Gy) | 17.6 Gy (6.1-29.3 Gy) | 19.8 Gy (11.0-32.4 Gy) | 20.5 (13.3-32.4 Gy) |
†
Includes carcinoma not otherwise specified (NOS) and non-small cell lung cancer NOS.
Abbreviations: CT=computed tomography; FEV1=force expiratory volume in 1 second; IMRT=intensity modulated radiation therapy; MLD=mean lung dose; PS=performance status; V5=volume receiving greater than 5 Gy; V10=volume receiving greater than 10 Gy; V20=volume receiving greater than 20 Gy; RP=radiation pneumonitis.